Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Papillomavirus Infections × Artesunate × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Intestinal Neoplasms 2 Colorectal Neoplasms 2 Papillomavirus Infections 1 CIN 2/3 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 5 Radiotherapy, Intensity-Modulated 5 Cisplatin 5 Carboplatin 5 Papillomavirus Vaccines 4 artesunic acid 3 artemisinin 3 Paclitaxel 3 Human Papillomavirus Recombinant Vaccine nonavalent 3 Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 3 artenimol 2 Vaccines, Synthetic 2 Taxes 2 Radiation 2 Imiquimod 2 GX-188 vaccine 2 Docetaxel 2 Albumin-Bound Paclitaxel 2 utomilumab 1 toripalimab 1 polyphenon E 1 infigratinib 1 fludarabine phosphate 1 fludarabine 1 aldesleukin 1 Viusid 1 Vaccines 1 VP-102 1 Therapies, Investigational 1 Specimen Handling 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05555862 2025-05-18

anal HSIL HIV-

Frantz Viral Therapeutics, LLC

Phase 2 Active not recruiting

Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon ⚡